The Cannabinoids Biopharma Company
RS Biotherapeutic’s mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life-changing medicines. RS BioTherapeutic’s first investigational compound (RSBT-001) is a patent-pending, semi-synthetic cannabidiolic acid complex in development to replace corticosteroids in addressing exacerbation and preventing progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
Our leadership team is comprised of industry leaders and specialists who are committed to the advancement of our vision and mission.
Meet the individuals on our advisory team.